CA - Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
2024-03-28 17:59:49 ET
Summary
- OLEMA Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted oncology therapies, with a focus on women's cancer.
- Their flagship drug, palazestrant, shows promising results for halting the progression of estrogen receptor-positive and HER2-negative breast cancer.
- The company has collaborations with Novartis and Pfizer and expects trial updates in 2024, but tangible FDA approvals and revenues are still a long way off.
- Despite promising developments, the long FDA approval and revenue generation timeline warrants a “hold” rating.
...
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path